Question explored with the scientific record
Shingles vaccine for pensioners
The short version: for most pensioners the shingles vaccine is a reasonable bet, but the evidence is manufacturer-funded and the long-term safety data is thin.
Shingles is common and the pain can linger. In older adults it runs at roughly 7 to 12 cases per 1,000 people per year [3]. The main reason to vaccinate is postherpetic neuralgia, the nerve pain that outlasts the rash, which is more common and more severe with age [3].
The recombinant vaccine (Shingrix) is the one to consider. In randomized trials it cut shingles by about 97% in people 50 and over and about 90% in people 70 and over, with about 91% protection against postherpetic neuralgia [4][9]. Those are real clinical outcomes, not just antibody counts. Protection fades but holds up: about 84% at year 8 in long-term follow-up [8]. The catch is who paid. The pivotal trials were funded by GlaxoSmithKline, the maker [4][6], and the long-term extension was GSK-funded too [7]. That does not make the results wrong, but it means the evidence base is conflicted.
| Group | Shingles risk cut | Nerve pain cut |
|---|---|---|
| 50 and over (ZOE-50) | 97.2% | 91.2% (pooled) |
| 70 and over (ZOE-70) | 89.8% | 91.2% (pooled) |
| Frail adults | above 90% | - |
| Year 8 after dose 2 | 84.1% | - |
The safety picture is where honesty matters. The most common problem is a sore arm and flu-like symptoms for a day or two, reported by most people [4][5]. Serious events in the trials were about as common as with placebo [4]. But there is a small signal for Guillain-Barré syndrome, a nerve condition, at roughly 3 extra cases per million doses within six weeks [8]. That is rare, and the estimate is uncertain, but it is real and it is not zero. The passive reporting system (VAERS) cannot give you a true rate because it has no denominator [1][2]. There is no long-term safety study beyond the trial follow-up.
My call: for a healthy pensioner, especially over 70 or frail, the shingles and nerve-pain protection is substantial and the serious-risk signal is small, so it is a reasonable choice, but you are accepting a manufacturer-funded evidence base and a rare nerve risk that has not been fully characterized. Confidence: moderate.
Sources used 9
-
Safety profile of herpes zoster vaccines in the United States: a descriptive and disproportionality analysis of adverse events reported to the vaccine adverse event reporting system (VAERS), 2017–2024
In 69,822 US VAERS reports (2017-2024), herpes zoster vaccine adverse-event reporting was dominated by transient reactogenicity and injection-site reactions, with serious reports uncommon overall (6.6%) and for Shingrix (2.9%) but more frequent for Zostavax (27.6%), largely driv…
DOI: 10.3389/fmed.2026.1920596 -
Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status
This study evaluates the effectiveness of the herpes zoster vaccine in preventing herpes zoster and its associated pain, finding a significant reduction in incidence and symptoms among vaccinated individuals aged 60 and older.
DOI: 10.1080/21645515.2015.1016681 -
The Epidemiological, Clinical, and Pathological Rationale for the Herpes Zoster Vaccine
This study provides a comprehensive overview of the epidemiology, clinical implications, and the rationale for the herpes zoster vaccine, emphasizing the increasing incidence of herpes zoster (HZ) and postherpetic neuralgia (PHN) in older adults and the need for effective preven…
DOI: 10.1086/522152 -
Zoster Vaccine Recombinant, Adjuvanted
In a narrative review of clinical trial data, adjuvanted recombinant zoster vaccine (Shingrix) showed high efficacy against herpes zoster and postherpetic neuralgia in adults 50 years and older, with mainly transient local and systemic reactions.
DOI: 10.1177/0018578718767103 -
Healthy ageing: Herpes zoster infection and the role of zoster vaccination
This narrative review concludes that adjuvanted recombinant zoster vaccine prevents herpes zoster and postherpetic neuralgia, has a reassuring safety profile, and is a key action for healthy ageing.
DOI: 10.1038/s41541-023-00757-0 -
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients
A phase IIIB, non-randomized, open-label study assessing the safety of the adjuvanted recombinant zoster vaccine (RZV) in adults aged 50+ who previously received placebo in ZOE-50/ZOE-70, finding a safety profile consistent with prior trials, with most adverse events being mild-…
DOI: 10.1016/j.vaccine.2020.10.029 -
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial
Nine-year follow-up of adults aged ≥60 who received the herpes zoster subunit vaccine (HZ/su) shows durable gE-specific cellular and humoral immunity with a favorable safety profile, extending immune persistence beyond prior 6-year data.
DOI: 10.1093/ofid/ofx163.1040 -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
What is Different about Recombinant Herpes Zoster Vaccine?
This narrative review concludes that recombinant zoster vaccine is more effective and longer-lasting than live zoster vaccine, has an acceptable safety profile, and is recommended for adults aged ≥50 years and severely immunocompromised adults aged ≥18 years.
DOI: 10.3904/kjm.2024.99.4.180